PharmaCyte Biotech
PMCB
26 hedge funds and large institutions have $1.58M invested in PharmaCyte Biotech in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 4 closing their positions.
1.46% less ownership
Funds ownership: 12.22% → 10.76% (-1.5%)
7% less funds holding
Funds holding: 28 → 26 (-2)
22% less capital invested
Capital invested by funds: $2.02M → $1.58M (-$445K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.1K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.73K |
| 3 |
Renaissance Technologies
New York
|
+$2.23K |
| 4 |
MCA
Maryland Capital Advisors
Chester,
Maryland
|
+$65 |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$220K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$54.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$35.8K |
| 5 |
BlackRock
New York
|
-$26.2K |
PMCB Hedge Fund Activity: Q3 2024 in Review
26 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q3 2024, worth a combined $1.58M — down 22% from $2.02M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PMCB and 2 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $4.1K. The largest seller was K2 Principal Fund, cutting an estimated $220K.
- 26 institutional investors held PharmaCyte Biotech (PMCB) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $1.58M of PharmaCyte Biotech stock for Q3 2024, down 22% quarter-over-quarter.
- 2 funds opened new PharmaCyte Biotech positions in Q3 2024 and 4 closed out, a net change of -2 holders.
- The largest PharmaCyte Biotech buyer in Q3 2024 was Schonfeld Strategic Advisors, an estimated $4.1K added.
- The largest PharmaCyte Biotech seller in Q3 2024 was K2 Principal Fund, an estimated $220K sold.
Based on aggregated 13F filings for Q3 2024.